AbbVie (ABBV) News Today $192.32 -2.68 (-1.37%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$192.38 +0.06 (+0.03%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is AbbVie Down Today?Toggle Visibility of Why Is AbbVie Down Today?AbbVie Inc. (NYSE: ABBV) has seen its shares move today amid a flurry of news, including a landmark licensing deal that broadens its oncology pipeline, supportive analyst ratings, legal victories, and revisions to earnings forecasts. Investors are weighing these developments as they assess AbbVie’s growth prospects and near-term outlook. Positive Sentiment: AbbVie signed an exclusive global licensing agreement for IGI’s first-in-class trispecific antibody ISB 2001 in oncology and autoimmune indications, paying a $700 million upfront fee and bolstering its immuno-oncology portfolio. IGI and AbbVie sign licence deal for cancer and autoimmune therapy Positive Sentiment: AbbVie defeated an investor class-action suit alleging Humira kickbacks, removing a key legal overhang on its flagship franchise. AbbVie Beats Investor Class Suit Over Alleged Humira Kickbacks Positive Sentiment: The Vanguard Group expanded its stake in AbbVie, signaling confidence from a major institutional investor. Vanguard Group Inc. Expands Stake in AbbVie Inc. Positive Sentiment: J.P. Morgan analyst Chris Schott maintained a Buy rating on AbbVie with a $200 price target, citing promising growth prospects and a stable outlook. AbbVie: A Strong Buy with Promising Growth Prospects and Stable Outlook Positive Sentiment: A Zacks report highlighted AbbVie’s edge over Bristol Myers on the back of strong Skyrizi and Rinvoq growth, which is offsetting Humira’s patent cliff. ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now? Neutral Sentiment: Cantor Fitzgerald trimmed its FY2025 EPS estimate for AbbVie to $11.84 (from $12.31) but kept an Overweight rating and a $210 target price. FY2025 EPS Estimates for AbbVie Reduced by Cantor Fitzgerald Neutral Sentiment: Leerink Partners slightly raised its FY2026 EPS forecast for AbbVie to $14.03 (from $14.01), reflecting long-term growth expectations. FY2026 EPS Estimates for AbbVie Raised by Leerink Partnrs Neutral Sentiment: An article on dividend investing listed AbbVie among healthcare names with attractive yields, underscoring its appeal to income-oriented portfolios. What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill Negative Sentiment: Leerink Partners cut its Q2 2025 EPS estimate for AbbVie to $2.87 (from $3.24), reflecting concerns about near-term headwinds. Leerink Partnrs Has Bearish Outlook for AbbVie Q2 Earnings Posted 1+ days agoAI Generated. May Contain Errors. ABBV Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period AbbVie Inc. (NYSE:ABBV) Stock Position Raised by Arizona State Retirement SystemJuly 12 at 8:45 AM | marketbeat.comBallentine Partners LLC Has $8.87 Million Position in AbbVie Inc. (NYSE:ABBV)July 12 at 8:06 AM | marketbeat.comFocused Wealth Management Inc Increases Stock Position in AbbVie Inc. (NYSE:ABBV)July 12 at 7:46 AM | marketbeat.comAbbVie Inc. (NYSE:ABBV) Shares Sold by Rational Advisors Inc.July 12 at 7:30 AM | marketbeat.com3 No-Brainer Dividend Stocks to Buy In JulyJuly 12 at 7:09 AM | 247wallst.comIFC Advisors LLC Makes New Investment in AbbVie Inc. (NYSE:ABBV)July 12 at 7:03 AM | marketbeat.com3 Dividend Growth Stocks to Buy and HoldJuly 12 at 6:40 AM | fool.comThe Smartest Dividend Stocks to Buy With $300 Right NowJuly 12 at 5:15 AM | fool.comIndia's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing dealJuly 11 at 4:09 PM | msn.comIGI and AbbVie sign licence deal for cancer and autoimmune therapyJuly 11 at 11:09 AM | finance.yahoo.comGlenmark-AbbVie Deal Lifts Optimism on India’s Biotech StocksJuly 11 at 11:09 AM | bloomberg.comDiversify Wealth Management LLC Buys 3,299 Shares of AbbVie Inc. (NYSE:ABBV)July 11 at 8:12 AM | marketbeat.com4,462 Shares in AbbVie Inc. (NYSE:ABBV) Acquired by Stegent Equity Advisors Inc.July 11 at 8:11 AM | marketbeat.comXponance Inc. Raises Stock Position in AbbVie Inc. (NYSE:ABBV)July 11 at 7:50 AM | marketbeat.com6,864 Shares in AbbVie Inc. (NYSE:ABBV) Bought by CrobanJuly 11 at 7:29 AM | marketbeat.comFidelis Capital Partners LLC Buys 1,560 Shares of AbbVie Inc. (NYSE:ABBV)July 11 at 7:29 AM | marketbeat.comWeil Company Inc. Has $468,000 Stock Holdings in AbbVie Inc. (NYSE:ABBV)July 11 at 7:12 AM | marketbeat.comAbbVie Inc. (NYSE:ABBV) Shares Bought by Cerity Partners LLCJuly 11 at 6:23 AM | marketbeat.comWhat Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the BillJuly 11 at 3:55 AM | fool.comFY2025 EPS Estimates for AbbVie Lowered by Cantor FitzgeraldJuly 11 at 2:16 AM | americanbankingnews.comLeerink Partnrs Has Bearish Outlook for AbbVie Q2 EarningsJuly 11 at 2:31 AM | americanbankingnews.comIndia’s Glenmark Pharma shares hit record high on AbbVie cancer drug dealJuly 10 at 12:56 AM | investing.comVanguard Group Inc. Expands Stake in AbbVie Inc. with Strategic Share AcquisitionJuly 10 at 12:35 AM | gurufocus.comGlenmark Pharma jumps on unit's cancer licensing deal with AbbVieJuly 10 at 11:55 PM | reuters.comWhy Is AbbVie Stock Trading Higher On Thursday?July 10 at 3:01 PM | benzinga.comAbbVie and Ichnos Glenmark sign licensing deal for trispecific antibodyJuly 10 at 1:44 PM | msn.comTesla robotaxi, AbbVie licenses Glenmark cancer drug, McDonald'sJuly 10 at 1:44 PM | finance.yahoo.comAbbVie Shares Climb on $700 Million Licensing Deal with IGI TherapeuticsJuly 10 at 1:44 PM | msn.comAbbVie and Genmab’s Epcoritamab Trial: A Promising Update for B-NHL TreatmentJuly 10 at 12:48 PM | tipranks.comAbbVie (ABBV) Secures Licensing Deal for Cancer Drug ISB 2001July 10 at 11:31 AM | gurufocus.comAbbVie stock jumps after $700 million licensing deal with IGI TherapeuticsJuly 10 at 11:31 AM | investing.comCode Waechter LLC Has $812,000 Stock Position in AbbVie Inc. (NYSE:ABBV)July 10 at 9:29 AM | marketbeat.comTelos Capital Management Inc. Decreases Stake in AbbVie Inc. (NYSE:ABBV)July 10 at 9:29 AM | marketbeat.comFY2025 EPS Estimates for AbbVie Reduced by Cantor FitzgeraldJuly 10 at 9:11 AM | marketbeat.comAlps Advisors Inc. Decreases Stake in AbbVie Inc. (NYSE:ABBV)July 10 at 9:09 AM | marketbeat.comAllworth Financial LP Has $31.22 Million Position in AbbVie Inc. (NYSE:ABBV)July 10 at 8:51 AM | marketbeat.comAbbVie in Immuno-Oncology Licensing Pact with IGI TherapeuticsJuly 10 at 8:42 AM | marketwatch.comAbbVie (NYSE:ABBV) HeadlineJuly 10 at 8:21 AM | gurufocus.comAbbVie (ABBV) Secures Exclusive Licensing for Innovative Therapy from IGI | ABBV Stock NewsJuly 10 at 8:21 AM | gurufocus.comAbbVie (ABBV) Secures Licensing Deal for Oncology Asset | ABBV Stock NewsJuly 10 at 8:21 AM | gurufocus.comMainStreet Investment Advisors LLC Cuts Stock Holdings in AbbVie Inc. (NYSE:ABBV)July 10 at 8:15 AM | marketbeat.comAlpine Woods Capital Investors LLC Cuts Stock Holdings in AbbVie Inc. (NYSE:ABBV)July 10 at 7:55 AM | marketbeat.comIndia's Glenmark Pharma unit, Abbvie sign exclusive licensing pactJuly 10 at 7:44 AM | reuters.comIchnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific AntibodyJuly 10 at 7:35 AM | globenewswire.comAbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific AntibodyJuly 10 at 7:30 AM | prnewswire.comFY2026 EPS Estimates for AbbVie Raised by Leerink PartnrsJuly 10 at 2:28 AM | americanbankingnews.comMorgan Stanley Maintained an Overweight Rating on AbbVie (ABBV)July 9, 2025 | msn.comAbbVie Inc. (NYSE:ABBV) Shares Bought by Bridges Investment Management Inc.July 9, 2025 | marketbeat.comNisa Investment Advisors LLC Decreases Stock Position in AbbVie Inc. (NYSE:ABBV)July 9, 2025 | marketbeat.comAbbVie Inc. (NYSE:ABBV) Shares Sold by Moloney Securities Asset Management LLCJuly 9, 2025 | marketbeat.com Get AbbVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter. Email Address ABBV Media Mentions By Week ABBV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABBV News Sentiment▼0.830.99▲Average Medical News Sentiment ABBV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABBV Articles This Week▼10362▲ABBV Articles Average Week Get AbbVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMGN News Today GILD News Today MRNA News Today ABT News Today BMY News Today JNJ News Today LLY News Today MRK News Today PFE News Today ZTS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ABBV) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
